Newronika has developed an innovative technology in Adaptive Deep Brain Stimulation for the treatment of symptoms incurred by patients suffering from Parkinson disease and other neurological diseases.
The company, thanks to its multidisciplinary team, provides the patient with the right stimulation at the right moment, thus enabling daily activities and improving the quality of life. Newronika has a considerable patent portfolio and promising clinical results. On February 2021, the firm obtained the CE mark for its device.
Atlante Ventures entered with an early stage investment in 2016, while Indaco Ventures I invested in the project at a later stage in 2019.